Transcode Therapeutics, INC. 8-K Filing
Ticker: RNAZ · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1829635
Sentiment: neutral
Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-12-11 08:09:07
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share RNAZ The Nasdaq Capital
Filing Documents
- tm2533194d1_8k.htm (8-K) — 25KB
- tm2533194d1_ex99-1.htm (EX-99.1) — 16KB
- tm2533194d1_ex99-1img02.jpg (GRAPHIC) — 5KB
- tm2533194d1_ex99-1img01.jpg (GRAPHIC) — 7KB
- tm2533194d1_ex99-1img04.jpg (GRAPHIC) — 3KB
- tm2533194d1_ex99-1img03.jpg (GRAPHIC) — 4KB
- tm2533194d1_ex99-1img05.jpg (GRAPHIC) — 3KB
- 0001104659-25-120146.txt ( ) — 242KB
- rnaz-20251211.xsd (EX-101.SCH) — 3KB
- rnaz-20251211_lab.xml (EX-101.LAB) — 33KB
- rnaz-20251211_pre.xml (EX-101.PRE) — 22KB
- tm2533194d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 11, 2025, TransCode Therapeutics, Inc. ("TransCode") issued a press release announcing a new collaboration to evaluate TransCode's lead therapeutic candidate, TTX-MC138, as part of the Quantum Leap Healthcare Collaborative ("Quantum Leap") PRE-I-SPY clinical trial platform. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 11, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TransCode Therapeutics, Inc. Date: December 11, 2025 By: /s/ Philippe Calais Philippe Calais Chief Executive Officer